Zoetis Inc. $ZTS Shares Sold by Groupama Asset Managment

Key Points

• Groupama Asset Management reduced its stake in Zoetis Inc. by 23.8%, selling 2,021 shares and leaving it with 6,481 shares valued at approximately $1,057,000.
• In contrast, Vanguard Group increased its holdings by 0.5%, now owning over 41.5 million shares valued at $6.8 billion, alongside other institutional investors also adjusting their positions.
• Zoetis reported earnings of $1.76 per share for the last quarter, exceeding estimates and representing a 4.2% increase in revenue compared to the previous year.

Groupama Asset Managment cut its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 23.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,481 shares of the company's stock after selling 2,021 shares during the quarter. Groupama Asset Managment's holdings in Zoetis were worth $1,057,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Navigoe LLC purchased a new position in Zoetis in the 4th quarter valued at about $30,000. Cornerstone Planning Group LLC lifted its stake in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after buying an additional 88 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its stake in Zoetis by 87.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after buying an additional 120 shares in the last quarter. Sound Income Strategies LLC lifted its stake in Zoetis by 141.4% in the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after purchasing an additional 164 shares in the last quarter. Finally, Bfsg LLC lifted its stake in Zoetis by 614.6% in the 1st quarter. Bfsg LLC now owns 293 shares of the company's stock worth $48,000 after purchasing an additional 252 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president owned 15,129 shares in the company, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.18% of the company's stock.

Zoetis Trading Up 0.5%

Shares of ZTS stock traded up $0.7080 during trading on Friday, hitting $156.3180. 2,426,297 shares of the stock traded hands, compared to its average volume of 3,495,215. The firm has a market capitalization of $69.28 billion, a P/E ratio of 26.91, a price-to-earnings-growth ratio of 2.51 and a beta of 0.88. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm's fifty day moving average price is $153.84 and its 200-day moving average price is $158.52. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ZTS shares. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and decreased their target price for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Piper Sandler raised their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, UBS Group decreased their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $202.43.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.